Evidence map›Paper›PMID 41249973›Full record

Trial reportBMC public health2025

Engagement of adolescent girls and young women into an early oral PrEP open-label study in Southern Africa: lessons learned from HPTN 082.

Miliswa Magongo, Nomsa Mhlanga, Sisa Nobanda, Charles Chasakara, Ntando Yola, Kathy Hinson, Marcus Bryan, Pumeza Mzizi, Thandekile Essien, Nicholas Hastings and 5 more

Registry-linked trialAbstract readClinical Trial, Phase IVMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02732730 (Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02732730 phase4completednot on this map

Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study

TypeinterventionalSponsorHIV Prevention Trials NetworkRan2016 to 2018Enrolled451ConditionsHIVArmsTruvada, Drug level counseling at Weeks 8 and 13
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Miliswa MagongoWits RHI, University of Witwatersrand, 22 Esselen Street, Hillbrow, Johannesburg, 2001, South Africa.
Nomsa MhlangaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Sisa NobandaDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Charles ChasakaraUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Ntando YolaDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Kathy HinsonFamily Health International (FHI 360), Durham, NC, USA.
Marcus BryanFamily Health International (FHI 360), Durham, NC, USA.
Pumeza MziziWits RHI, University of Witwatersrand, 22 Esselen Street, Hillbrow, Johannesburg, 2001, South Africa.
Thandekile EssienWits RHI, University of Witwatersrand, 22 Esselen Street, Hillbrow, Johannesburg, 2001, South Africa.
Nicholas HastingsFamily Health International (FHI 360), Durham, NC, USA.
Makhosazane Nomhle Ndimande-KhozaWits RHI, University of Witwatersrand, 22 Esselen Street, Hillbrow, Johannesburg, 2001, South Africa.
Linda-Gail BekkerDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Nyaradzo MgodiUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Connie CelumUniversity of Washington, Seattle, WA, USA.
Sinead Delany-MoretlweWits RHI, University of Witwatersrand, 22 Esselen Street, Hillbrow, Johannesburg, 2001, South Africa. sdelany@wrhi.ac.za.

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
UZ-UCSF Clinical Trials UnitU01AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIRENJE, ZVAVAHERA MIKE · 2007 to 2011
$49.3M
National Institute of Allergy and Infectious Diseases (NIAID)) to HPTN UM1-AI068619NIAID NIH HHS U01 AI069436NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069436
6 · The paper itself

Abstract

backgroundAdolescent girls and young women (AGYW) in southern Africa face a high risk of HIV acquisition. Consistent use of daily oral pre-exposure prophylaxis (PrEP) can significantly mitigate this risk. We used the Good Participatory Practice Framework (GPP) to summarize lessons learned from engaging AGYW in an open-label PrEP trial, highlighting successful strategies that enhanced trial engagement.

methodsThe HIV Prevention Trials Network (HPTN) 082 was an open-label study conducted from 2016 to 2018 that evaluated PrEP uptake and adherence in AGYW 16- to 25-year-old without HIV living in Cape Town and Johannesburg, South Africa, and Harare, Zimbabwe. Overall, 646 AGYW were screened for eligibility and 416 were enrolled. Fieldwork reflections, meeting summaries, Community Advisory Board (CAB) meeting minutes, and other project records were analyzed to synthesize lessons for stakeholder engagement relevant to PrEP introduction and service delivery.

resultsUsing the GPP framework, several key lessons were identified. Early and comprehensive engagement with a broad range of stakeholders throughout the trial was crucial. Youth stakeholders played a significant role in shaping communication materials, clinic design, the package of HIV and non-HIV care, and referral pathways for supportive services. Identifying myths and misconceptions during early stakeholder engagements allowed for tailored PrEP education materials and approaches for PrEP-naïve communities. Parents and caregivers emerged as an essential group to engage to ensure support, even when adolescents were of legal age to provide consent. Peers were identified as important sources of information, support and referral for screening during the trial. Innovations to enhance engagement and results dissemination included the development of youth-led videos and peer support clubs.

conclusionsIntroducing daily oral PrEP for young African AGYW required multiple strategies that were culturally sensitive, age-appropriate, and inclusive of peers, partners, parents, and other influential adults. These strategies were essential for fostering a supportive environment for PrEP use and enhancing engagement in the trial. Lessons learned from PrEP introduction to AGYW in southern Africa have relevance for future trials and HIV prevention programs.

trial registrationClinicalTrials.gov NCT02732730, 13 November 2018.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisAdministration, OralAdolescentAdultAfrica, SouthernFemaleHumansSouth AfricaYoung AdultAnti-HIV AgentsAGYWClinical trialsCommunity engagementGPPHIV preventionPre-exposure prophylaxisSub-Saharan africa

Identifiers

PMID41249973
PMCPMC12625398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.